BIA Hopeful New Government Proposals will Help Boost UK as a Location for Clinical Trials
News Oct 26, 2012
The BIA has welcomed government proposals to make the UK a more favourable location for innovative biopharmaceutical research and development through its consultation on the Research and Bolar Exceptions.
The proposals seek to add clarity to the UK's position on the types of research and clinical trials that can be carried out in the UK without giving rise to a risk of patent infringement.
In a submission to the government on a previous informal consultation in July 2011, the BIA called for a level playing field so that developers of innovative products were afforded the same level of protection and certainty as others.
Steve Bates, Chief Executive of the BIA, said: "We welcome the government's commitment to reviewing this issue and ensuring everything is done to make the UK an attractive location to conduct research and clinical trials."
Bates continued, "Biopharmaceutical companies invest more in R&D in the UK than any other sector and we have all the tools to continue to develop new medicines for patients. We look forward to engaging with government on this issue to ensure any barriers to continued such investment is removed."
John Murphy, Chair of the BIA's Intellectual Property Advisory Committee, said: "Companies need to have confidence and certainty in the legal framework within which they operate particularly where intellectual property is concerned."
Murphy continued, "It is important to provide clarity regarding the UK's interpretation of the Research and Bolar Exceptions so that innovative drug developers operate on a level playing field and we hope this consultation will provide the opportunity to address these issues."
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018